drugset / Trial / NCT03825705
A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
A single-arm, open-label clinical trial, focus on the safety and efficacy of TQB2450 injection combined with Anlotinib hydrochloride capsule in patients with advanced biliary adenocarcinoma/hepatocellular carcinoma
Timeline
- Start
- 2019-04-23
- Primary completion
- 2021-01-01
- Completion
- 2021-01-01
Publications
- Gong C, Huang J, Cao D, Liu T, Cai Q, You S, Sun Y, Jiang Z, Wang W, Yang L, Zhao H, Zhang W, Zhou A. Serum BDNF helps identify favorable subgroups in HCC patients treated with PD-L1 inhibitors and anti-angiogenic TKIs. Ther Adv Med Oncol. 2025 Dec 23;17:17588359251407052. doi: 10.1177/17588359251407052. eCollection 2025.
- Zhou J, Sun Y, Zhang W, Yuan J, Peng Z, Wang W, Gong J, Yang L, Cao Y, Zhao H, Chen C, Wang W, Shen L, Zhou A. Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Hepatology. 2023 Jan 1;77(1):65-76. doi: 10.1002/hep.32548. Epub 2022 Aug 18.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benmelstobart | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Catequentinib | Small molecule | 10 mg | Oral |